AMAndres Martinez

Andres Martinez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Andres Martinez has a total of 95 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Developing and Implementing Provider-Training and Evidence-Based Tools to Support Pre-exposure Prophylaxis (PrEP) Decision-Making and Increase PrEP Adherence Among Young Men Who Have Sex With Men: Protocol for the PrEP Choice Longitudinal Cohort Study

    by Crissi Rainer, Rebecca Schnall, Mary R Tanner, Carla A Galindo, Karen W Hoover, Sylvie Naar, Maeve Brin, Andres Martinez, Haomiao Jia, Maria Mendoza, et al.

    Background: Despite the availability of highly effective HIV pre-exposure prophylaxis (PrEP), uptake and adherence to PrEP among young men who have sex with men (YMSM) remains low, limiting its impact on the prevention of HIV infection. Strategies that incorporate an array of prevention options and provide YMSM and their providers with tailored education and support tools, including tools to support shared decision-making, are needed. Objective: The goals of the Centers for Disease Control and Prevention (CDC)–funded PrEP Choice study include the development and deployment of CDC guideline–consistent PrEP provider training and the implementation of evidence-based provider- and client-facing PrEP education and support tools. Under this initiative, the CDC funded 2 research projects, Florida State University (the Expanding PrEP in Communities of Color [EPICC] project), and Columbia University (the mChoice project). Methods: Providers from both projects will complete the PrEP Choice online training, which was developed to educate providers on PrEP options and how to engage clients in open discussions around sexual health and PrEP options. EPICC project providers will also attend online tailored motivational interviewing (TMI) training sessions, and mChoice project providers will view a training video on cultural competency and humility in PrEP care. Following training, each project will enroll a cohort of 400 participants receiving care from study providers and follow them for 12-18 months. Participants will complete online surveys every 3 months and provide biomarkers to assess PrEP adherence. Electronic health record (EHR) data will be collected every 6 months to provide additional information on clinic attendance, PrEP prescriptions, and HIV/sexually transmitted infection (STI) testing. Each project will provide cohort participants with a unique digital health tool to support the PrEP choice and ongoing adherence. The study will assess the effectiveness of training and educational and support tools in practice and the critical factors associated with the successful uptake of and adherence to PrEP by participants. The study will also monitor patterns of PrEP use among YMSM, including types of PrEP and switching between types. Results: Formative work to develop and prepare the tools for implementation was completed in 2023. The EPICC project began provider training in early 2024, and the mChoice project began in spring 2024. Cohort enrollment for both projects began after provider training began. Conclusions: Given the changing PrEP landscape, implementation of provider education and tools to maximize uptake and adherence is needed. By delivering culturally competent and interactive provider training on PrEP options, the study will help providers counsel and guide participants on the effective and safe use of PrEP. The digital health tools created will support participant adherence to help them optimize PrEP benefits. Through the cohort design, the PrEP Choice study will provide real-world data about PrEP use that will be critical for informing future guidelines and tools. International Registered Report Identifier (IRRID): DERR1-10.2196/64186


  • Open Access

    Meta-analysis of Pregnancy Events in Biomedical HIV Prevention Trials in Sub-Saharan Africa: Implications for Gender Transformative Trials

    by Lara Lorenzetti, Nhi Dinh, Cason Whitcomb, Andres Martinez, Manju Chatani, Breanne Lievense, Definate Nhamo, Catherine Slack, Natalie Eley, Kathleen MacQueen

    Historically, pregnant and lactating populations (PLP) have been excluded or disenrolled from biomedical HIV prevention trials, despite being more likely to acquire HIV during pregnancy and the post-partum period. We conducted a meta-analysis of pregnancy events in biomedical HIV prevention trials in sub-Saharan Africa to support trialists moving toward more inclusive clinical and implementation studies. We searched peer-reviewed literature reporting pregnancy events and contraceptive requirements in HIV prevention trials between 2001 and 2022. We hypothesized four variables to explain variation: contraceptive requirements, study start year, study product, and sub-region. We fit a meta-analytic model to estimate individual effect sizes and sampling variances, then conducted sub-group analyses to assess moderating effects. We identified 38 references for inclusion, across which the proportion of pregnancy events was 8% (95% confidence interval [CI]: 6–10%) with high heterogeneity (I2 = 99%). Studies not requiring contraceptives (21%, 95%CI: 7–48%) reported a significantly higher proportion of pregnancy events than studies requiring two methods (5%, 95%CI: 2–10%). Studies launched between 2001 and 2007 (11%, 95%CI: 8–16%), microbicide gel trials (12%, 95%CI: 8–18%), and studies conducted in Western Africa (28%, 95%CI: 13–51%) reported higher proportions of pregnancy events than reference groups. Together, these variables have a moderating effect on pregnancy events (p < 0.0001), explaining 63% of heterogeneity in trials. Results describe how, over time, more stringent contraceptive requirements reduced pregnancy events, which ensured necessary statistical power but limited reproductive choice by participants. With the move toward continuing PLP on experimental products, trialists can utilize estimated pregnancy events reported here to inform strategies that accommodate participants’ changing fertility preferences.


  • Open Access

    Developing and Implementing Provider-Training and Evidence-Based Tools to Support Pre-exposure Prophylaxis (PrEP) Decision-Making and Increase PrEP Adherence Among Young Men Who Have Sex With Men: Protocol for the PrEP Choice Longitudinal Cohort Study (Preprint)

    by Crissi Rainer, Rebecca Schnall, Mary R Tanner, Carla A Galindo, Karen W Hoover, Sylvie Naar, Maeve Brin, Andres Martinez, Haomiao Jia, Maria Mendoza, et al.

    BACKGROUND Despite the availability of highly effective HIV pre-exposure prophylaxis (PrEP), uptake and adherence to PrEP among young men who have sex with men (YMSM) remains low, limiting its impact on the prevention of HIV infection. Strategies that incorporate an array of prevention options and provide YMSM and their providers with tailored education and support tools, including tools to support shared decision-making, are needed. OBJECTIVE The goals of the Centers for Disease Control and Prevention (CDC)–funded PrEP Choice study include the development and deployment of CDC guideline–consistent PrEP provider training and the implementation of evidence-based provider- and client-facing PrEP education and support tools. Under this initiative, the CDC funded 2 research projects, Florida State University (the Expanding PrEP in Communities of Color [EPICC] project), and Columbia University (the mChoice project). METHODS Providers from both projects will complete the PrEP Choice online training, which was developed to educate providers on PrEP options and how to engage clients in open discussions around sexual health and PrEP options. EPICC project providers will also attend online tailored motivational interviewing (TMI) training sessions, and mChoice project providers will view a training video on cultural competency and humility in PrEP care. Following training, each project will enroll a cohort of 400 participants receiving care from study providers and follow them for 12-18 months. Participants will complete online surveys every 3 months and provide biomarkers to assess PrEP adherence. Electronic health record (EHR) data will be collected every 6 months to provide additional information on clinic attendance, PrEP prescriptions, and HIV/sexually transmitted infection (STI) testing. Each project will provide cohort participants with a unique digital health tool to support the PrEP choice and ongoing adherence. The study will assess the effectiveness of training and educational and support tools in practice and the critical factors associated with the successful uptake of and adherence to PrEP by participants. The study will also monitor patterns of PrEP use among YMSM, including types of PrEP and switching between types. RESULTS Formative work to develop and prepare the tools for implementation was completed in 2023. The EPICC project began provider training in early 2024, and the mChoice project began in spring 2024. Cohort enrollment for both projects began after provider training began. CONCLUSIONS Given the changing PrEP landscape, implementation of provider education and tools to maximize uptake and adherence is needed. By delivering culturally competent and interactive provider training on PrEP options, the study will help providers counsel and guide participants on the effective and safe use of PrEP. The digital health tools created will support participant adherence to help them optimize PrEP benefits. Through the cohort design, the PrEP Choice study will provide real-world data about PrEP use that will be critical for informing future guidelines and tools. INTERNATIONAL REGISTERED REPORT DERR1-10.2196/64186

  • Open Access

    Consensus recommendations for measuring the impact of contraception on the menstrual cycle in contraceptive clinical trials

    by Amelia C. L. Mackenzie, Stephanie Chung, Emily Hoppes, Nora Miller, Anne E. Burke, Sharon L. Achilles, C. Leigh Allen, Luis Bahamondes, Diana L. Blithe, Vivian Brache, et al.

    Objective We sought to develop consensus recommendations for improved measurement of contraceptive-induced menstrual changes (CIMCs) in contraceptive clinical trials to build upon previous standardization efforts. Study Design We undertook a virtual consensus-building process using a modified Delphi approach, incorporating aspects of Nominal Group Technique and the Jandhyala method. The process consisted of four half-day meetings, developing recommendations within five topical working groups, a series of consensus questionnaires to assess recommendation agreement on a 4-point Likert-like scale, and opportunities for input and feedback throughout the process. Recommendations required at least 75% consensus to be included. Results Our interdisciplinary group—from 26 organizations and 13 countries in five global regions across academia, nonprofit research organizations, the pharmaceutical industry, and funding agencies— developed 44 consensus recommendations. These included recommendations on standardization, patient-reported outcome measure development aligned with current regulatory guidance, trial design, protocol development, participant recruitment, data collection, data analysis, and areas for exploratory research. Seven recommendations were deemed a priority by over 85% of our group. Conclusion Using a formal consensus-building process, we reached high levels of agreement around recommendations for more standardized and patient-centered measurement of CIMCs in contraceptive clinical trials, now and in the future. Implications statement Consensus recommendations on measuring bleeding changes and related outcomes in contraceptive clinical trials can improve reporting of standardized, patient-centered outcomes in future product labeling. These improvements can enable providers to offer more relevant counseling on contraceptives and permit greater comparability and data synthesis across trials to inform clinical guidance.


  • Open Access

    1521. High frequency of vitamin D deficiency in hospitalized patients with HIV: A prospective study in Colombia

    by Yeimer Ortiz-Martínez, Leidy Herrera-Caviedes, Claudia Figueroa-Pineda, María J Melo-Amaya, Andrés F Henao Martínez

    Vitamin D deficiency is prevalent in people living with HIV (PLWH) and is linked to various negative health outcomes. Despite numerous studies in other regions, information regarding vitamin D status and its determinants among PLWH in Latin America is scarce. This study aimed to determine the frequency of vitamin D deficiency in hospitalized patients with HIV in Colombia and identify associated risk factors. Table 1 A total of 73 PLWH were included in the study. 75.3% were men with a mean age of 40.6 ± 11.85 years. 50.6% were on antiretroviral therapy (ART) at the time of admission. 69.8% had a CD4 count ≤ 200 cells/mm3, and 63% had a viral load > 10,000 copies/ml. The in-hospital mortality was 19.35%. The median (IQR) 25(OH)D level was 21.28 ng/mL (13-27.8). Vitamin D deficiency was present in 49.3% of the participants, with 19.1% having severe deficiency. Insufficiency and suboptimal levels were found in 56.1% and 79.4%, respectively. No significant association was found between vitamin D deficiency and mortality or HIV-related factors, including ART, viral load, and CD4 count (Table 1). However, after multivariate analysis, albumin less than 3 g/dL was significantly associated with vitamin D deficiency (aOR 3.86, 95% CI: 1.37-10.85; p=0.01). This is the first prospective study in Colombia that highlights the high frequency of vitamin D deficiency in hospitalized patients with HIV. The finding of a significant association between hypoalbuminemia and vitamin D deficiency suggests that malnutrition or TNF-mediated cachexia may be contributors to this problem. Further studies are needed to explore the implications of vitamin D deficiency in this population and to develop appropriate interventions. All Authors: No reported disclosures

  • Open Access

    1406. A Systematic Quality Improvement Initiative to Improve Chagas Disease Screening in Patients with HIV at a Large Safety Net Clinic in Denver

    by Lilian Vargas Barahona, Andrés F Henao Martínez, Margaret P McLees, Edward Gardner, Kellie Hawkins

    Chagas Disease (CD) is a neglected parasitic disease that affects people living in continental Latin America. Immigrants from these countries or those born to mothers from Latin America are at risk of developing disease. Detection of cases before end-organ damage has occurred is crucial for treatment to be beneficial. Patients with HIV (PWH) may be at high risk of reactivation and death. We sought to screen PWH at risk of CD that receive medical care in the safety net hospital for the Denver area. Chagas disease screening process in patients with HIV in Denver Health, March 2022 - March 2023 Between March 2021 and March 2022, a total of 265 patients completed testing (81.5%). 89.8% were male and the mean age was 45.4 years (SD +/- 11.5). Most patients had controlled HIV (mean CD4 624 +/- 303.5 cells/µL, HIV viral load < 30 cps/mL in 92%). Most patients were born in Mexico (80%), followed by El Salvador (5%). Three patients had a positive test, yielding a prevalence of 1.1%. One of these patients had an already confirmed and treated infection. The other 2 patients had uncontrolled HIV with CD4 count < 200 cells and have been lost to follow-up with inability to obtain confirmatory testing. Using a 2.2% prevalence of serologic positivity for CD in Hispanic patients, 90 patients at risk will need to be screened in order to detect a positive patient. Due to increased awareness of CD in our primary care clinics, a parallel 3-fold increase in testing in non-HIV patients was seen in the study period. Chagas disease screening in patients at risk can be performed in clinics that provide care for patients with HIV. Obtaining a second confirmatory test is challenging and processes to facilitate blood collection should be implemented to not delay testing. Increased awareness of medical providers leads to increased screening for this disease. Edward Gardner, MD, Cepheid: Grant/Research Support|Gilead Sciences: Grant/Research Support|ViiV Healthcare: Grant/Research Support

  • Open Access

    908. Clinical Characteristics and Outcomes of Cytomegalovirus Disease in HIV-Negative Non-Transplant Patients, a Propensity Score Match Analysis

    by Ixchel T Salter, Michaele-Francesco Corbisiero, Daniel B Chastain, Jose G Montoya, Raymund R Razonable, Andrés F Henao Martínez

    Cytomegalovirus (CMV) infects millions in the US and is a source of comorbidity among immunocompromised patients. Despite its prevalence, there is limited data on clinical characteristics or outcomes among HIV-negative, non-transplant (NHNT) patients in population-based cohorts. We aim to evaluate a multicenter US-based network to obtain clinical characteristics and outcomes of NHNT patients with CMV disease and explore potential prognostic clinical characteristics implicated in increased morbidity and mortality. This is a US-based multicenter, population-based, retrospective cohort study. We queried TrinetX, a global research network, to identify patients with a CMV disease by ICD-10-CM codes and serum and PCR > 5000 IU/mL. We captured comorbidities diagnosed within 90 days of CMV infection diagnosis, symptoms noted within 30 days, and outcomes of interest at 30 days and 1 year. Primary outcome was all-cause mortality. Secondary outcomes were hospitalization and CMV disease-related complications. We performed a propensity score-matched analysis comparing clinical characteristics among patients who survived versus non-survivors at 90 days. NHNT patients with CMV disease often have underlying comorbidity, commonly aplastic anemia, and neoplasms. CMV disease was associated with thrombosis and a high risk of hospitalization and mortality. Vascular disease, sepsis, high viral load, and cell lysis markers were prognostic factors for mortality in this cohort. Raymund R. Razonable, MD, Allovir: Endpoint Adjudication Committee|American Society of Transplantation: Board Member|Gilead: Grant/Research Support|Novartis: DSMB|Regeneron: Grant/Research Support|Roche: Grant/Research Support

  • Open Access

    Effects of the COVID-19 pandemic on maternal and perinatal health service utilisation and outcomes in Mozambique: an interrupted time series analysis

    by Megan M Lydon, Joaquim Vilanculos, Andres Martinez, Américo Barata, Emily Keyes

    Objectives To measure the effects of the COVID-19 pandemic on maternal and perinatal health services and outcomes in Mozambique. Design This is an observational study analysing routine service delivery data using interrupted time series analysis. We used 43 months of district-level panel data with April 2020 as the point of interruption, adjusting for seasonality and population growth to analyse service utilisation outcomes. Setting The 222 public health facilities in Nampula Province, Mozambique, from January 2018 to July 2021. Outcome measures The change in the number of antenatal care (ANC) visits and facility deliveries, and the change in the rate of adverse birth outcomes at pandemic onset and over time compared with expected levels and trends, respectively. Results There were no significant disruptions to ANC at pandemic onset. Following this, there was a significant monthly increase of 29.8 (18.2–41.4) first ANC visits and 11.3 (5.5–17.2) ANC visits within the first trimester per district above prepandemic trends. There was no significant change in the number of fourth ANC visits completed. At the onset of COVID-19, districts experienced a significant decrease of 71.1 (−110.5 to −31.7) facility deliveries, but the rate then increased significantly above prepandemic trends. There was no significant increase in any adverse birth outcomes during the pandemic. Conversely, districts observed a significant monthly decrease of 5.3 uterine rupture cases (−9.9 to −0.6) and 19.2 stillbirths (−33.83 to −4.58) per 100 000 facility deliveries below prepandemic trends. There was a significant drop of 23.5 cases of neonatal sepsis/100 000 facility deliveries per district at pandemic onset. Conclusion Despite pandemic interference, Nampula Province saw no disruptions to ANC, only temporary disruptions to facility deliveries and no increases in adverse birth outcomes. ANC visits surprisingly increased, and the rates of uterine rupture, stillbirth and neonatal sepsis decreased, suggesting that Nampula Province may offer insights about health system resilience.


  • Cross-country comparability of a social-emotional skills assessment designed for youth in low-resource environments

    by Nina Menezes Cunha, Andres Martinez, Patrick Kyllonen, Sarah Gates

    We evaluate the measurement invariance of a 48-item instrument designed to measure general social and emotional skills of youth in low resource environments. We refer to the skills measured as positive self-concept, negative self-concept, higher order thinking skills, and social and communication skills. These skills are often associated with economic development and can be used to evaluate programs designed to enhance economic development. Our evaluation is based on a sample of 1,794 in and out-of-school youth from Uganda and Guatemala’s Western Highlands. We conduct the analyses using a multiple group confirmatory factor analysis approach, breaking the sample by country, gender, and socio-economic status (high vs. low). Overall, our analysis points to strong invariance for all four measures across the different groups being compared. These findings contribute to the validity of the instrument as a tool for better understanding youth in diverse, developing economies.


  • Open Access

    Maternal nutrition intervention and maternal complications in 4 districts of Bangladesh: A nested cross-sectional study

    by Catherine S. Todd, Zakaria Chowdhury, Zeba Mahmud, Nazia Islam, Sadia Shabnam, Musarrat Parvin, Alissa Bernholc, Andres Martinez, Bachera Aktar, Kaosar Afsana, et al.

    Maternal morbidity is common in Bangladesh, where the maternal mortality rate has plateaued over the last 6 years. Maternal undernutrition and micronutrient deficiencies contribute to morbidity, but few interventions have measured maternal outcomes. We compared reported prevalence of antepartum, intrapartum, and postpartum complications among recently delivered women between maternal nutrition intervention and control areas in Bangladesh. We conducted a cross-sectional assessment nested within a population-based cluster-randomized trial comparing a nutrition counseling and micronutrient supplement intervention integrated within a structured home-based maternal, newborn, and child health (MNCH) program to the MNCH program alone in 10 sub-districts each across 4 Bangladesh districts. Eligible consenting women, delivering within 42–60 days of enrollment and identified by community-level health workers, completed an interviewer-administered questionnaire detailing the index pregnancy and delivery and allowed review of their home-based care register. We compared pooled and specific reported antepartum, intrapartum, and postpartum complications between study groups using hierarchical logistic regression. There were 594 women in the intervention group and 506 in the control group; overall, mean age was 24 years, 31% were primiparas, and 39% reported facility-based delivery, with no significant difference by study group. There were no significant differences between the intervention and control groups in household-level characteristics, including reported mean monthly income (intervention, 6,552 taka, versus control, 6,017 taka; p = 0.48), having electricity (69.6% versus 71.4%, p = 0.84), and television ownership (41.1% versus 38.7%, p = 0.81). Women in the intervention group had higher recorded iron and folic acid and calcium supplement consumption and mean dietary diversity scores, but reported anemia rates were similar between the 2 groups (5.7%, intervention; 6.5%, control; p = 0.83). Reported antepartum (69.4%, intervention; 79.2%, control; p = 0.12) and intrapartum (41.4%, intervention; 48.5%, control; p = 0.18) complication rates were high and not significantly different between groups. Reported postpartum complications were significantly lower among women in the intervention group than the control group (33.5% versus 48.2%, p = 0.02), and this difference persisted in adjusted analysis (adjusted odds ratio [AOR] = 0.51, 95% CI 0.32–0.82; p < 0.001). For specific conditions, odds of retained placenta (AOR = 0.35, 95% CI 0.19–0.67; p = 0.001), postpartum bleeding (AOR = 0.37, 95% CI 0.15–0.92; p = 0.033), and postpartum fever/infection (AOR = 0.27, 95% CI 0.11–0.65; p = 0.001) were significantly lower in the intervention group in adjusted analysis. There were no significant differences in reported hospitalization for antepartum (49.8% versus 45.1%, p = 0.37), intrapartum (69.9% versus 59.8%, p = 0.18), or postpartum (36.1% versus 29.9%, p = 0.49) complications between the intervention and control groups. The main limitations of this study are outcome measures based on participant report, non-probabilistic selection of community-level workers’ catchment areas for sampling, some missing data for variables derived from secondary sources (e.g., dietary diversity score), and possible recall bias for reported dietary intake and supplement use. Reported overall postpartum and specific intrapartum and postpartum complications were significantly lower for women in intervention areas than control areas, despite similar rates of facility-based delivery and hospitalization for reported complications, in this exploratory analysis. Maternal nutrition interventions providing intensive counseling and micronutrient supplements may reduce some pregnancy complications or impact women’s ability to accurately recognize complications, but more rigorous evaluation is needed for these outcomes.